Pressure intensifies on Novartis as bolt-on deal strategy faces major test

Monday, September 14, 2026Robert BarrieView original

Share prices tumbled last week after a key asset from Novartis’ $12bn Avidity deal fumbled in a Phase III trial.

Read the full article on the original site.